NASDAQ:KLDO - Kaleido Biosciences Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $8.00
  • Forecasted Upside: 16.79 %
  • Number of Analysts: 3
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$6.85
▼ -0.12 (-1.72%)
1 month | 3 months | 12 months
Get New Kaleido Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KLDO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KLDO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$8.00
▲ +16.79% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Kaleido Biosciences in the last 3 months. The average price target is $8.00, with a high forecast of $8.00 and a low forecast of $8.00. The average price target represents a 16.79% upside from the last price of $6.85.
Hold
The current consensus among 3 polled investment analysts is to hold stock in Kaleido Biosciences.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
5/2/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
7/31/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
10/23/2020

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/14/2020JPMorgan Chase & Co.Initiated CoverageUnderweightHigh
i
8/10/2020Morgan StanleyBoost Price TargetEqual Weight$7.00 ➝ $8.00High
i
8/5/2020Canaccord GenuityReiterated RatingBuyHigh
i
7/15/2020Morgan StanleyLower Price TargetEqual Weight$8.00 ➝ $7.00Medium
i
5/21/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$8.00Medium
i
9/19/2019Chardan CapitalReiterated RatingBuyMedium
i
Rating by G. Amusa at Chardan Capital
4/23/2019Chardan CapitalInitiated CoverageBuy ➝ Buy$17.50Low
i
Rating by T. Feehley at Chardan Capital
3/25/2019Morgan StanleyInitiated CoverageOverweight ➝ Overweight$17.00Medium
i
3/25/2019Canaccord GenuityInitiated CoverageBuy$19.00Medium
i
3/25/2019JPMorgan Chase & Co.Initiated CoverageNeutral ➝ Neutral$15.00Medium
i
3/25/2019Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$20.00Medium
i
(Data available from 10/23/2015 forward)
Kaleido Biosciences logo
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company offers product candidates for the treatment of urea cycle disorders; hepatic encephalopathy; infections caused by multi-drug resistant bacteria; cardiometabolic and liver diseases; and immune oncology. It has a collaboration agreement with Gustave Roussy Cancer Center to develop microbiome metabolic therapies in immuno-oncology; a research collaboration with Washington University School of Medicine to explore the influence of microbiome metabolic therapies on microbial and host physiology and metabolism; and a research collaboration with Janssen to prevent childhood-onset of atopic, immune, and metabolic conditions. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.
Read More

Today's Range

Now: $6.85
$6.59
$7.02

50 Day Range

MA: $7.91
$5.09
$11.33

52 Week Range

Now: $6.85
$2.82
$11.89

Volume

6,314 shs

Average Volume

195,864 shs

Market Capitalization

$243.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A